SLC5A2 and heart failure: Recent groundbreaking clinical trials have demonstrated that SGLT2 inhibitor therapies not only enhance blood glucose control but also reduce cardiovascular events and hospitalizations due to heart failure in patients with type 2 diabetes [5].